TPTatjana Pejcic

Tatjana Pejcic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tatjana Pejcic has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Therapeutic effects of reslizumab in patients with severe eosinophilic asthma

    by Borislav Božanić, Ivana Stanković, Stefan Šajnović, Nikola Rančev, Ana Srbulović-Božanić, Jelena Aleksić, Dragana Stojiljković, Kristina Jović, Marija Marinković, Zoran Stamenković, et al.

    Introduction: The beneficial therapeutic effects of anti-IL-5 biological therapy in severe asthma have been confirmed in randomized controlled trials. The aim of this study was to evaluate the effects of reslizumab therapy in patients with severe eosinophilic asthma. Methods: This retrospective-prospective study included 18 patients. The following parameters were analyzed: age, body mass index (BMI), and the number of administered doses of biological therapy; absolute peripheral blood eosinophil count - BEC (cells/μL), at baseline and after three months of therapy; baseline fractional exhaled nitric oxide (FeNO) levels and total IgE levels; as well as prebronchodilator FEV₁ and Asthma Control Test (ACT) scores, at baseline and during twelve months of therapy. Results: All patients in the study group were female, with a mean age of 53.9 years and a mean BMI of 29.1 kg/m². An average of 12.25 doses of the drug was administered. The baseline BEC was 402.3 cells/ μL; administration of the first dose resulted in a statistically significant reduction after 24 hours, which was maintained after three months of follow-up. The mean FeNO value was 30.1 ppb, and the mean total IgE level was 160.9 IU/mL. The mean baseline FEV₁ was 57.7% of predicted, with higher values maintained throughout the follow-up period. The mean ACT score before initiation of therapy was 10.8 and was significantly higher during further follow-up. Conclusion: Biological therapy with reslizumab in overweight and obese female patients with a confirmed diagnosis of severe asthma and elevated biomarkers of the Th2 immune response results in a significant reduction in symptoms and stabilization of lung function, achieving adequate disease control in more than three-quarters of patients. The therapeutic effects are maintained over a one-year follow-up period.

  • Biochemical characteristics of malignant pleural effusions

    by Kristina Jović, Marko Bjelaković, Katarina Jović, Zoran Stamenković, Dragana Stojiljković, Jelena Aleksić, Stefan Šajnović, Tatjana Pejčić

    Introduction: Malignant pleural effusions (MPE) represent a common complication of advanced malignancies and are typically characterized as exudates. The aim of this study was to analyze the biochemical characteristics of MPE, with special emphasis on the application of Light's criteria and the serum-pleural albumin gradient (SPAG), as well as to assess potential discrepancies between these diagnostic approaches. Methods: This retrospective study included 49 patients with pleural effusion associated with malignancy, treated from January 2025 to January 2026. The malignant nature of pleural effusion was confirmed either cytologically or based on radiological evidence of pleural invasion. Biochemical parameters of pleural fluid and serum were analyzed, including proteins, albumin, lactate dehydrogenase (LDH), glucose, creatinine, and cholesterol. Effusions were classified according to Light's criteria and SPAG. Results: The majority of patients had lung tumors (61%), with a mean age of 70.9 ± 10.5 years. Biochemical analysis revealed an exudative profile, with a mean pleural fluid/serum protein ratio of 0.615 ± 0.117 and LDH ratio of 1.864 ± 1.323. According to Light's criteria, 96% of effusions were classified as exudates. In contrast, SPAG classified 20% of effusions as transudates. The mean SPAG value was 10.87 ± 4.31 g/L. Conclusion: Malignant pleural effusions predominantly exhibit biochemical characteristics of exudates, although with considerable variability in certain parameters. The observed discrepancy between Light's criteria and SPAG highlights the need for careful interpretation of biochemical findings and a broader diagnostic approach in the evaluation of MPE.

  • The significance of STOP-BANG, Epworth and Berlin questionnaires in predicting obstructive sleep apnea confirmed by respiratory poligraphy

    by Jelena Aleksić, Miloš Jovanović, Tatjana Pejčić, Dragana Stojiljković, Stefan Šajnović, Kristina Jović, Borislav Božanić, Milan Radović, Desa Nastasijević-Borovac, Zoran Stamenković

    Introduction: Obstructive sleep apnea (OSA) is a common sleep-disordered breathing disorder whose diagnosis requires polysomnography, which sometimes limits availability. The aim: To determine the diagnostic value of the STOP-BANG questionnaire, Epworth Sleepiness Scale (ESS), and Berlin Questionnaire in predicting OSA severity confirmed by respiratory polygraphy. Methods: A retrospective analysis included 105 patients with diagnosed OSA (AHI ≥ 5) treated at the Pulmonology Clinic of the University Hospital Center Niš. Results: The mean age was 52.95 ± 11.25 years, BMI 34.85 ± 6.68 kg/m², and the mean AHI 34.20 ± 21.13 events/h. Severe OSA was present in 53.3% of the subjects. All three questionnaires showed a statistically significant correlation with AHI (Spearman r = 0.361-0.370, p < 0.001). For the prediction of moderate to severe OSA (AHI ≥ 15), STOP-BANG with a threshold of ≥ 5 had the best AUC of 0.759, sensitivity of 90.5% and specificity of 38.1%. For the prediction of severe OSA (AHI ≥ 30), ESS showed the best AUC of 0.704 with balanced sensitivity (66.1%) and specificity (61.2%). The Berlin questionnaire had high sensitivity (92.9%) but low specificity for both severity levels. The optimal thresholds according to the Youden index differed from the standard ones: ESS ≥ 7 for moderate to severe, ≥ 12 for severe OSA; STOP-BANG ≥ 7 for both levels. Conclusion: STOP-BANG questionnaire with a threshold of ≥ 5 is the most useful screening tool for the identification of moderate to severe OSA, while ESS has the best performance for the prediction of severe OSA.

  • Open Access

    Clinical Characteristics and Survival of Patients with Idiopathic Pulmonary Fibrosis: Analysis of the Serbian Cohort from the EMPIRE Registry

    by Sanja Dimic-Janjic, Mihailo Stjepanovic, Slobodan Belic, Dragan Vukosavljevic, Ivan Milivojevic, Nikola Trboljevac, Nikola Nikolic, Slavko Stamenic, Maja Stojanovic, Kristina Stosic, et al.

    Background/Objectives: Idiopathic pulmonary fibrosis (IPF) registries are established to enhance understanding of its natural history. Methods: Serbia (RS) participated in the EMPIRE (European Multi-Partner IPF Registry) from June 2015 to October 2022, involving four centers. The registry included patients over 18 diagnosed with IPF based on the 2011 international criteria. We aimed to gather key clinical, functional, and survival data, along with treatment information for IPF patients in RS, using a centralized electronic case report for consistency. Results: 188 RS patients participated (median age at diagnosis 65, 63.8% male, 51% smoking history, 56% radiological usual interstitial pneumonia (UIP) pattern). At the diagnosis, median forced vital capacity (FVC) was 73.7% and diffusion capacity for carbon monoxide (DLCO) was 38%. At initiation of antifibrotic therapy, median FVC was 73.2% (71.5% for deceased, 75.8% for survivors (p = 0.455), and DLCO was 33.8% (19.9% for deceased, and 35.6% for survivors (p = 0.046)). The median long-term survival from diagnosis was 29.4 months (95% CI: 22.6–36.2 months), and 9.4 months (95% CI: 5.9–12.9 months) from the initiation of therapy, with no difference in the duration of antifibrotic treatment between survivors and deceased (p = 0.598). Conclusions: The RS EMPIRE cohort represents a younger, less comorbid population with fewer smokers and more probable UIP, factors linked to a favorable prognosis. Nevertheless, survival was poorer than expected, mainly due to advanced disease severity at the time of antifibrotic initiation, as indicated by lower DLCO. These findings highlight the importance of earlier diagnosis and treatment before significant physiological decline to improve outcomes.


  • Open Access

    The role of adrop predictive model in assessing the intrahospital mortality risk in patients with community-acquired pneumonia

    by Borovac Desa Nastasijević, Borislav Božanić, Tatjana Pejčić, Lidija Ristić, Ivana Stanković, Milan Radović, Zoran Stamenković, Stefan Šajnović, Miloš Jovanović

    Background: community-acquired pneumonia (cap) is the leading cause of death among respiratory infectious diseases. Initial assessment of CAP severity and risk of intrahospital mortality is important for initial desicion in which setting and how to treat patients. In clinical practice we use more predictive scores. Aim: we aimed to determine the accuracy of the curb-65 and a-drop scoring system in predicting intrahospital mortality risk in patients with CAP hospitalized at our institution during the 15-months period. Methods: we made a retrospective analysis of medical hystories data of 248 patients hospitalized from octobar 2023 to decembar 2024. For each patient the curb-65 and a-drop score were calculated and treatment outcome was assessed. In predicting risk of intrahospital mortality, we calculated and compared area under curve (auc) for each score. Result: from the examined group, 32 patients (12.9%) died. The risk of in-hospital mortality for curb-65 and adrop score was: auc 0.793 and 0.807, respectively. There was no difference between adrop and curb-65 model (dauc 0.0148; p = 0.4883), while adrop score showed better sensitivity in predicting mortality (84.37%, youden index j 0.4317) for values >1. Curb-65 score is better in survival-prediction. Conclusion: the a-drop scoring system have similar predictive value as curb-65, but is better in predicting intrahospital mortality.

  • Controversies in the use of fluoroquinolones: Have we understood the "warning letter" correctly?

    by Tatjana Pejčić

    Pharmacovigilance is important in monitoring the occurrence and prevention of adverse drug reactions. The use of Warning letter is a way to attract the attention of the doctors, but also the obligation to limit and/or warn about the use of the drug in certain conditions and comorbidities. Quinolones and fluoroquinolones are an important group of antibiotics that, due to their efficiency and good compliance, are often used in the treatment of various infections. Indications for the use of fluoroquinolones include infections of the respiratory tract, ear, throat and nose, invasive otitis externa caused by Pseudomonas aeruginosa, infections of the urinary tract, skin and soft tissues, bones, joints, pelvic organs, gastrointestinal infections, eradication of Salmonella germs and severe systemic infections. In order to ensure the safe use of fluoroquinolones in patients, and according to the announcements of ALIMS, based on the evidence of other drug agencies (e.g. European Medicines Agency - EMA and others), the prescription of fluoroquinolones should be prohibited for patients who have had aortic dissection (absolute risk). Patients at risk of aortic aneurysm and dissection are at relative risk and should be allowed fluoroquinolones after benefit-risk assessment and consideration of other therapeutic options. This group would also include patients with predisposing conditions for the occurrence and development of aneurysms (aneurysmal disease in family history, earlier occurrence of aneurysm or aortic dissection, Marfan syndrome, vascular form of Ehlers-Danlos syndrome, Takayasu's arteritis, giant cell arteritis of the arteries, Behçet's disease, hypertension and atherosclerosis), as well as patients with congenital or existing heart valve disease, connective tissue disorder (Marfan syndrome or Ehlers-Danlos syndrome), Turner syndrome, Behçet's disease, hypertension, rheumatoid arthritis and infective endocarditis. For all other infections with/or without comorbidities, prescribing fluoroquinolone can be as common as for other antibiotics, following antibiotic prescribing recommendations according to current national and other guidelines, with suggestions given in the "Summary of Drug Characteristics" and "Medication Instructions".

  • Open Access

    Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection

    by Milan Radovic, Lidija Ristic, Zorica Ciric, Violeta Dinic Radovic, Ivana Stankovic, Tatjana Pejcic, Milan Rancic, Dragan Bogdanovic

    Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection Milan Radovic,1,2 Lidija Ristic,1,2 Zorica Ciric,1,2 Violeta Dinic-Radovic,3 Ivana Stankovic,1,2 Tatjana Pejcic,1,2 Milan Rancic,1,2 Dragan Bogdanovic4 1Department of Internal Medicine, Faculty of Medicine, University of Nis, 2Clinic for Lung Diseases, 3Clinic for Gastroenterology and Hepatology, Clinical Centre of Nis, 4Public Health Institute Nis, Nis, Republic of Serbia Background: During the treatment phase of active pulmonary tuberculosis (PTB), respiratory function impairment is usually restrictive. This may become obstructive, as a PTB-associated airflow obstruction (AFO) or as a later manifestation of underlying COPD.Purpose: The aim of the study was to examine the potential causes and risks for AFO development in PTB by exploring the aspects of spirometry limitations and clinical implications for the underlying COPD detection, taking into account various confounding factors.Patients and methods: Prospective, nest case–control study on 40 new cases of PTB with initial restrictive respiratory function impairment, diagnosed and treated according to the directly observed treatment short course (DOTS) strategy.Results: From all observed patients, 37.5% of them developed AFO upon the completion of PTB treatment, with significantly increased average of forced vital capacity (%) (P<0.01). Their changes in forced expiratory volume in the first second (%) during the PTB treatment were strongly associated with the air pollution exposure in living (0.474%–20.971% for 95% confidence interval [CI]; P=0.041) and working environments (3.928%–20.379% for 95% CI; P=0.005), initial radiological extent of PTB lesions (0.018%–0.700% for 95% CI; P=0.047), leukocyte count (0.020%–1.328% for 95% CI; P=0.043), and C-reactive protein serum level (0.046%–0.205% for 95% CI; P=0.003) compared to the other patients. The multivariate logistic regression analysis model shows initial radiological extent of pulmonary tuberculosis lesions (OR 1.01–1.05 for 95% CI; P=0.02) and sputum conversion rate on culture (OR 1.02–1.68 for 95% CI; P=0.04) as the most significant predictors for the risk of AFO development.Conclusion: AFO upon PTB treatment is a common manifestation of underlying COPD, which mostly occurs later, during the reparative processes in active PTB, even in the absence of major risk factors, such as cigarette smoking and biomass fuel dust exposure. Initial spirometry testing in patients with active PTB is not a sufficient and accurate approach in the detection of underlying COPD, which may lead to their further potential health deterioration. Keywords: tuberculosis, pulmonary, respiratory function tests, lung diseases, obstructive


    • 1 February 2014
      • Vol. 11  (1) , 37-43

    Role of D-dimer in predicting mortality in patients with community-acquired pneumonia.

    by Desa Nastasijević Borovac, Tatjana Radjenović Petković, Tatjana Pejčić, Ivana Stanković, Irena Janković, Zorica Ćirić, Milan Rančić

    To determine whether D-dimer in patients with communityacquired pneumonia (CAP) can predict mortality risk better than standard biomarkers. White blood cell (WBC), C-reactive protein (CRP) and D-dimer in 129 patients with CAP were analyzed. The recommended Pneumonia Severity Index (PSI) score was used to classify CAP patients into five groups according to the severity of disease (Group PSI I-V), and for predicting mortality. Additionally, the patients were divided in surviving and non-surviving group. White blood cell and CRP were not in correlation with the severity of CAP and the risk of mortality. The correlation between plasma D-dimer and severity of CAP was found (r=0.4993; p less than 0.001). The level of D-dimer was significantly higher in nonsurviving (2498.38 ± 1248.83 ng/mL) than in surviving patients (966.44 ± 968.73 ng/mL) (p less than 0.001). In predicting mortality risk, D-dimer showed sensitivity of 0.84 (cut of >1538 mg/mL), specificity 0.86 and AUC 0.859 (95%CI; 0.787-0.914). Pneumonia Severity Index in predicting of mortality risk for cut of > PSI III showed sensitivity of 0.92, specificity 0.62 and AUC 0.868 (95%CI; 0.797-0.921). There was no statistical difference between AUC of PSI and D-dimer (delta AUC= 0.00895) (p=0.9005). Coagulation abnormalities were presented in older patients with severe infections and comorbidity. Plasma D-dimer correlated better than standard inflammatory markers with severity of disease and risk of mortality in patients with CAP. In predicting mortality risk, D-dimer did not show difference among the PSI score.


  • Open Access

    Acute–Phase Inflammatory Response in Patients with Pulmonary Tuberculosis

    by Milan Radović, Tatjana Pejčić, Ivana Stanković, Lidija Ristić, Milan Rančić, Zorica Ćirić

    The main issue in patients with pulmonary tuberculosis (PTB) represents the impossibility of the host immune response to express bactericidal function and the sterilization of lesions depends exclusively on the specific antimicrobial chemotherapy. In order to investigate the value of acute-phase inflammatory response markers in patients with newly confirmed extensive PTB, there was designed a clinical study with 80 patients, of whom 40 had active disease (experimental group), while other 40 had inactive sequellar disease without comorbidity (control group). The examined groups were homogenous with respect to the patient’s general demographic characteristics. In the experimental group, 20.0% of the patients had an initial bacterial infection of the lower respiratory tract, while their average value of acute-phase systemic inflammatory markers was initially, before the antituberculosis treatment, significantly elevated compared to the control group. At the end of the treatment, values of erythrocyte sedimentation rate in the first hour (SE) and serum C-reactive protein (CRP) significantly decreased (SE-p < 0.001, CRP-p < 0.001), together with the value of the leukocyte count (Le) and serum fibrinogen (Le-p < 0.001, fibrinogen-p < 0.001). Multivariate linear regression analysis proved a significant correlation between baseline serum fibrinogen level with positive history of contact with active TB patient and initial radiological extent of PTB lung lesions. The values of the acute-phase inflammatory response markers in active PTB have its clinical significance in the assessment of unfavourable course of disease in extensive disseminated form of PTB as well as in the occurrence of complications associated with low respiratory tract bacterial superinfection.


    • 1 August 2013
      • Vol. 10  (2) , 266-71

    Nutrition disorder and systemic inflammation in patients with chronic obstructive pulmonary disease.

    by Zorica Cirić, Ivana Stanković, Tatjana Pejčić, Lidija Ristić, Milan Rančić, Milan Radović, Desa Nastasijević-Borovec

    To detect nutrition disorders (underweight and obesity) in patients with chronic obstructive disease (COPD) and presence of systemic inflammation by determination of inflammatory mediators serum values C-reactive protein (CRP), tumor necrosis factor alpha (TNF-α) and leptin. The examination involved 85 patients with COPD. Nutrition categories were defined by body mass index (BMI). Fat free mass (FFM) was evaluated by mid upper-arm circumference (MUAC) and fat mass (FM) by tricipital skin-fold thickness (TFS). Values of TNF-α and leptin were measured by standardized ELISA kits and, CRP by latex turbidimetry. There were 14 (16.5%) underweight patients, 28 (32.9%) normal, 28 (32.9%) pre-obese and 15 (17.6%) obese. Values of MUAC and TSF were significantly different among the nutrition categories (p=0.000). The lowest MUAC and TSF values were in the underweight, and the highest in the obese. There was no significant difference of CRP and TNF-α among nutrition categories. Leptin of the underweight and normal nutrition was significantly different from leptin of the pre-obese and obese (p=0.000). The highest CRP and the lowest TNF-α and leptin were in the underweight patients. The obese had the lowest CRP (although increased as compared to normal values) and the highest leptin, while the pre-obese had the highest TNF-α. Two basic nutrition disorders (underweight and obesity) were manifested in COPD patients. The inflammatory profile differs between underweight COPD patients and obese. Probably that happens due to systemic inflammation, and in part due to dysfunction of adipose tissue.